Zenas BioPharma, Inc.
Market Cap
$862.50M
P/E Ratio
-2.29
EPS
$-8.44
Dividend Yield
0.00%
52-Week Range
$8.51 — $44.60
Volume
686.24K
Avg Volume
771.92K
Beta
-0.51
Get alerted when ZBIO hits your target price.
Free — enter your email to get started
P/E (TTM)
-2.29
Forward P/E
—
PEG Ratio
0.03
P/S (TTM)
95.80
P/B (TTM)
4.12
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-1.57%
ROA (TTM)
-0.98%
ROIC
—
Gross Margin
-3.80%
Operating Margin
-21.64%
Net Margin
—
Debt/Equity
0.33
Current Ratio
5.61
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.73%
EPS Growth (5Y)
-0.73%
Sales Growth (3Y)
-0.30%
Sales Growth (5Y)
-0.30%
EPS Est (This Year)
$-4.83
EPS Est (Next Year)
$-4.73
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$7.38
Price Target Range
Consensus Target: $37.00(91.5% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
102.84K
Outstanding Shares
44.64M
Float
10.46M
Free Float %
23.44%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2024-09-13
Employees
130
CEO
Leon Oliver Moulder Jr.
Index Membership
—
Website
https://zenasbio.com
Zenas BioPharma, Inc. (ZBIO) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $862.50M, a P/E ratio of -2.29, ZBIO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ZBIO against other stocks using dozens of fundamental and technical filters.
Zenas BioPharma, Inc. (ZBIO) has a trailing twelve-month (TTM) P/E ratio of -2.29. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Zenas BioPharma, Inc. (ZBIO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $862.50 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.